NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-23
Reading VCYT? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on revenue growth and operational efficiency. The current thesis state is intact, driven by recent strong financial results and management's commitment to growth.
Valuation is considered expensive compared to peers, with a durable premium. The market appears to have high expectations, as indicated by a 19% expectations gap.
Fundamentals are likely to continue improving, as management has consistently delivered on revenue growth, operating income, and cash from operations. However, there is a low probability of missing earnings, but past performance shows a risk of significant misses.
The thesis hinges on the performance of sector bellwethers like TMO, DHR, and IDXX. Positive earnings and guidance from these companies could support VCYT, while any negative trends could pose risks.
Overall, VCYT's position is strong, but the elevated risk in the sector and expensive valuation warrant careful observation. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mixed' to 'mild_favorable'.
Yes, our read has strengthened. The latest earnings beat supports this improvement, indicating that recent financial performance remains strong and in the top half of its industry. There are no current threats to the thesis, suggesting a stable outlook for the company.
as of 2026-07-23
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This shows growth may slow down. It will affect future revenue.
Confirms:Q2 testing revenue growth reported below 14% year over year.
Disproves:Q2 testing revenue growth reported at or above 14% year over year.
Why it matters: A fall in gross margin may mean higher costs or pricing issues hurting profits.
Confirms:Q2 gross margin falls below 70%.
Disproves:Gross margin remains above 70%.
Why it matters: Successful launches could lead to more revenue. They may also help the market grow.
Confirms:Prosigna LDT and TrueMRD launches are expected in 2026.
Disproves:Delays or issues reported regarding the launches of Prosigna LDT and TrueMRD.
Why it matters: If operating income grows over 50%, it shows good cost management. This may help how investors feel.
Confirms:Operating income reported to grow above 50% in Q2.
Disproves:Operating income growth was less than 50% in Q2.
Why it matters: A higher adjusted EBITDA margin means better profits. This is key for long-term success.
Confirms:Adjusted EBITDA margin in Q2 is over 26%.
Disproves:Adjusted EBITDA margin in Q2 is below 25%.
Why it matters: Slow growth in Decipher could mean trouble. It may hurt overall revenue.
Confirms:Decipher revenue growth reported below 30% year over year.
Disproves:Decipher revenue growth reported at or above 30% year over year.
Why it matters: A decline could show problems in operations. This may impact future investments.
Confirms:Cash from operations was less than $30 million.
Disproves:Cash from operations reported at or above $30 million.
